Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q3 2022 Earnings Conference Call November 8, 2022 8:00 AM ET

Company Participants

David Connolly - Investor Relations and Corporate Communications

David Meeker - Chairman, President and Chief Executive Officer

Jennifer Chien - Executive Vice President, Head of North America

Yann Mazabraud - Executive Vice President, Head of International

Hunter Smith - Chief Financial Officer

Conference Call Participants

Philip Nadeau - Cowen and Company

Dae Gon - Stifel

Corinne Jenkins - Goldman Sachs

Joseph Stringer - Needham & Company

Michael Higgins - Ladenburg

Operator

Good day, and thank you for standing by. Welcome to the Rhythm Pharmaceuticals Third Quarter 2022 Earnings Conference Call. [Operator Instructions]

I would now like to hand the conference over to your speaker today, Dave Connolly, Investor Relations and Corporate Communications at Rhythm Pharmaceuticals. Please go ahead.

David Connolly

Thank you, and good morning, everybody. I'm Dave Connolly, IR and Corporate Communications here at Rhythm. For those of you participating via the conference call, our slides can be accessed and controlled by going to the investors section on the Investors page of our website at ir.rhythmtx.com. This morning, we had a press release that provides our third quarter financial results and business update, which is available on our website.

And as listed on Slide 2 here today with me in Boston for the conference call are David Meeker, Chair, President and Chief Executive Officer; Jennifer Chien, Executive Vice President, Head of North America; Hunter Smith, our Chief Financial Officer; and Yann Mazabraud, Executive Vice President and Head of International is on the line joining us from France.

With Slide 3, I'll remind you this call contains remarks concerning future expectations, plans and prospects, which constitute forward-looking statements actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in our most recent annual or quarterly report on file with the SEC. In addition, any forward-looking statements represent our views as only of today and should not be relied upon as representing our views as of any subsequent dates. We specifically disclaim any obligation to update such statements.

With that, I'll turn the call over to David, who will begin on Slide 5.

David Meeker

Thank you, Dave, and good morning, everyone, and thank you for joining our third quarter earnings call. So we had a really strong quarter. Last week, we presented the full Phase II hypothalamic obesity data set, and we will review that data briefly on today's call, but the real focus of today is on the progress we are making with our commercial launches in both the U.S. and Europe. BBS is a really good rare disease opportunity, both in terms of the number of patients potentially needing treatment and the syndromic nature of the disease, which facilitates patient identification.